The world's first vaccine for cervical cancer, named GARDASIL, becomes available to Australian women Monday, the vaccine's Australian distributor, CSL Limited, announced.

"With over 40 Australian women undergoing surgery daily to remove pre-cancerous or cancerous cervical lesions, the available of GARDASIL has been welcomed by health professionals nationally," CSL Limited said in a statement.

CSL Limited is a global, specialty biopharmaceutical company that develops, manufactures and markets products to treat and prevent serious human medical conditions. The company's headquarters is in Melbourne, capital of Australia's state of Victoria.

"The long-awaited vaccine will help prevent cervical cancer, as well as other human papillomavirus (HPV)-related cancers and diseases caused by four HPV types (6, 11, 16 and 18, which are included in the vaccine)," the company said.

These are the most common types of HPV affecting women's health and account for 70 percent of cervical cancer cases, a significant proportion of cervical abnormalities and 90 percent of genital wart cases, according to the company.

The vaccine is recommended for girls and women aged from 12 to 26.

Australian women are encouraged by professionals to visit doctors to see if the vaccine is suitable for them.

Together with regular pap smears, women can protect themselves against cervical abnormalities, according to professionals.

The vaccine was developed initially in Australia and then manufactured in the United States.